Stephanie Holland

Conference Coverage

Cognitive Function Similar Between Patients With mCRPC Treated With Abiraterone Acetate or Enzalutamide

01/25/2024

Results from the ACE study suggest that patients with metastatic castration-resistant prostate cancer treated with either abiraterone acetate or enzalutamide have a comparable composite cognitive outcome, though patients treated with...

Results from the ACE study...

01/25/2024

Oncology

News

Addition of Pembrolizumab to Perioperative Chemotherapy Increased Survival, Response Among Patients With Resectable, Early-Stage NSCLC

08/02/2023

Stephanie Holland ;

According to a phase 3 study, adding pembrolizumab to perioperative chemotherapy significantly improved survival and response with similar overall survival among patients with resectable, early-stage NSCLC, compared to chemotherapy alone.

According to a phase 3 study,...

08/02/2023

Oncology

News

Neoadjuvant Chemotherapy And Surgical Resection vs Concomitant Chemoradiotherapy Did Not Improve OS Among Patients With Cervical Cancer

11/15/2023

Stephanie Holland ;

According to results from the phase 3 EORTC-55994 trial, neoadjuvant chemotherapy and surgical resection did not significantly improve 5-year overall survival compared to standard-of-care concomitant chemoradiotherapy among patients with...

According to results from the...

11/15/2023

Oncology

News

Radiotherapy Omission Among Younger, Postmenopausal Patients With PT1N0 Unifocal Breast Cancer and Favorable Tumor Biology

01/12/2024

Stephanie Holland ;

Long-term follow-up results from the IDEA study suggest that younger postmenopausal patients with PT1N0 unifocal invasive breast cancer harboring favorable biological features can potentially omit radiotherapy and experience high disease...

Long-term follow-up results from...

01/12/2024

Oncology

News

Nivolumab Added to Perioperative Chemotherapy Improved Response, Survival Among Patients With Resectable Stage IIIA/B NSCLC

09/01/2023

Stephanie Holland ;

According to results from a phase 2 study, the addition of nivolumab to perioperative chemotherapy improved pCR and prolonged OS compared to chemotherapy alone among patients with resectable stage IIIA or IIIB NSCLC.

According to results from a...

09/01/2023

Oncology

News

Addition of Ovarian Suppression to Adjuvant Tamoxifen Significantly Improved DFS Among Premenopausal Patients With ER-Positive Breast Cancer

12/14/2023

Stephanie Holland ;

According to post-trial follow-up results from the ASTRRA trial, adjuvant tamoxifen plus ovarian function suppression significantly improved DFS rate with no negative impact on OS among premenopausal patients with pretreated estrogen...

According to post-trial...

12/14/2023

Oncology

Conference Coverage

Fianlimab Plus Cemiplimab Exhibits High Clinical Activity and Tolerable Safety in Advanced Melanoma

06/19/2023

Stephanie Holland ;

Data from a phase 1 trial show that combined treatment with fianlimab plus cemiplimab exhibits high clinical activity and tolerable safety in advanced melanoma, consistent with other approved combinations of immune checkpoint inhibitors in...

Data from a phase 1 trial show...

06/19/2023

Oncology

FDA Approval

FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations

01/20/2024

Stephanie Holland ;

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

Based on results from cohort 1...

01/20/2024

Oncology

Conference Coverage

Standard of Care Superior to Olaparib With or Without Cediranib Among Patients With Relapsed, Platinum-Sensitive Ovarian Cancer

10/26/2023

Stephanie Holland ;

According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.

According to data from the phase...

10/26/2023

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/31/2024

Stephanie Holland ;

Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.

Long-term follow-up data from...

01/31/2024

Oncology